COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

Search Clinical Trials

Clinical Trials Category

Reset

All of Us Research Program

Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.

17 results for "Cancer" and "Head and Neck Cancers" and "Early Phase/Multiple Disease Site Cancers"

A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study Of TNB-486, A Bispecific Antibody, In Subjects With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma

This is a Phase 1, First-in-Human clinical trial, meaning that it is the first study where TNB-486 will be given to humans. This study is open-label, meaning that everyone on the study will receive study drug, at various doses.
The purpose of the Study is:
• To find the highest dose of the study drug that can be given without causing severe side effects.
• To identify side effects of the study drug at different doses.
• To gather early information about how well the study drug treats lymphoma
• To measure the amount of the study drug in the blood at different timepoints after study drug administration, at different doses.
• To evaluate biomarkers in your blood or other parts of your body. A biomarker is a substance in your blood or other location that may tell us something about your disease, indicate how your disease is progressing, or provide information about how effective a study drug is.
Protocol No
TENEOBIO-TENEOTWO-TNB486-001
Sub Category
Hematologic/Blood Related Cancers, Early Phase/Multiple Disease Site Cancers

A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers

This study is to investigate the study drug in patients with a specific type of cancer called human papillomavirus 16-positive (HPV 16+) cancers. HPV 16+ cancers include head and neck, cervical, anal, vaginal, vulvar, and penile cancers. The main goal of the study is to determine whether HB-201 and HB-202 are effective in the treatment of human papillomavirus 16 positive (HPV 16+) confirmed cancers.
Protocol No
HOOKIPA-H-200-001
Sub Category
Gynecologic Cancers, Early Phase/Multiple Disease Site Cancers, Head and Neck Cancers

A Phase 1/2, Dose Escalation Safety And Tolerability Study Of AO-176 As Monotherapy And In Combination With Bortezomib And Dexamethasone In Adults With Relapsed Or Refractory Multiple Myeloma

You are being asked to participate in this study because you have multiple myeloma and your disease has returned after receiving treatment (recurrent disease) or it is no longer responding to your most recent treatment (refractory disease). Arch Oncology, the sponsor of the clinical trial, is studying AO-176 by itself or in combination with either dexamethasone or with both dexamethasone and bortezomib, as a potential treatment for people with recurrent or refractory multiple myeloma
Protocol No
ARCH-AO-176-102
Sub Category
Hematologic/Blood Related Cancers, Early Phase/Multiple Disease Site Cancers

Establishment Of A National Biorepository To Advance Studies Of Immune-Related Adverse Events

This study is being done to answer the following questions: Why do some patients experience serious side effects from immunotherapies, and why do other patients not experience these side effects? How can we identify these patients and prevent, reduce and treat these side effects more effectively? To answer these questions, it is helpful to have clinical data and samples collected from patients who have experienced these side effects from immunotherapy. For example, by studying blood samples collected before and after side effects occur, researchers can look for markers that may predict ...
Protocol No
ALLIANCE-A151804
Sub Category
Gastrointestinal Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers

A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy

Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
Protocol No
ACCRU-SC-1601
Sub Category
Hematologic/Blood Related Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Eye/Orbital Cancers, Endocrine Cancers, Breast Cancers, Brain and Spine Cancers

A Phase 1, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndrome

The purpose of the study is to find the answers to these research questions:
What are the side effects of MGD006?
What is the highest dose of MGD006 that can be given safely?
How long does MGD006 stay in the blood?
How long does it take for MGD006 to leave the body?
Is MGD006 a possible treatment for AML?
Protocol No
MACROGENICS-CP-MGD006-01
Sub Category
Hematologic/Blood Related Cancers, Early Phase/Multiple Disease Site Cancers

A Multi-Center, Open Label Phase 1/2 Study Of Cyt-0851, An Oral Rad51 Inhibitor, In Patients With Relapsed/Refractory B-Cell Malignancies And Advanced Solid Tumors

his clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of the oral RAD51 inhibitor CYT-0851 in patients with relapsed/refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose for evaluation in these patients.
Protocol No
CYTEIR-CYT-0851-01-REFMAL639
Sub Category
Hematologic/Blood Related Cancers, Early Phase/Multiple Disease Site Cancers, Sarcoma, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Breast Cancers

An Open-label, First-in-human, Single Agent, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Antitumor Activity of SAR442085 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

The purpose of the escalation phase is to determine the maximum tolerated dose and to determine the recommended dose that is to be used in the expansion phase (Part B) of the study. In the escalation phase, the study will determine the best dose level which will minimize the risk of side effects during testing.
Protocol No
SANOFI-TED16132
Sub Category
Hematologic/Blood Related Cancers, Early Phase/Multiple Disease Site Cancers

A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

NGM120, given as an injection, is designed to block a factor that is associated with cancer. NGM120 has shown in various animal models of cancer to reduce tumor size and improve symptoms of cancer.
Protocol No
NGM-18-0402
Sub Category
Gastrointestinal Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers

A Phase Ib/II, Open-label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with CHOP or CHP-Polatuzumab Vedotin in Patients with B-Cell Non-Hodgkin Lymphoma

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
Protocol No
HOFFMANN-LAROCHE-GO40515
Sub Category
Hematologic/Blood Related Cancers, Early Phase/Multiple Disease Site Cancers

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Protocol No
TORAY-950P1V02
Sub Category
Breast Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers